Skip to content

Strengthen luteal phase support after dual trigger in sub-optimal ovarian responders: an exploratory, single center, pilot randomized controlled trial

Strengthen luteal phase support after dual trigger in sub-optimal ovarian responders: an exploratory, single center, pilot randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500098020
Enrollment
Unknown
Registered
2025-02-28
Start date
2025-02-28
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

control group :Routine LPS with Progesterone gel 90 mg/d+ Oral Dydrogesterone 10 mg bid on the first day after oocytes retrieval
Experimental group :Strengthen LPS with HCG 2000 IU q3d*5 plus Progesterone gel 90 mg/d+ Oral Dydrogesterone 10 mg bid on the first day after oocytes

Sponsors

Guangdong Women and Children Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 43 Years

Inclusion criteria

Inclusion criteria: 1: Suboptimal responder in accordance with Poseidon criteria type 1 and type 2: AFC>= 5,AMH >= 1.2 ng/mL, Number of retrieved embryos:4-9; 2: Rule out uterine abnormalities: No abnormalities were found in HSG or HP examination, or the abnormalities were handled; 3: Age: >=20 years; 4: BMI=18-28kg/m^2 5: IVF or ICSI treatment with a diagnosis of infertility; 6: Voluntarily sign an informed consent form; 7: Patients who will have fresh embryo transfer.

Exclusion criteria

Exclusion criteria: 1: III~IV endometriosis or adenomyosis; 2: Other factors that affect embryo implantation, such as untreated hydrosalpinx, uterine malformations, uterine submucosal fibroids, intrauterine adhesions, etc; 3: Patients with chromosomal abnormalities requiring PGT; 4: Combined with uncontrolled endocrine diseases (such as hypertension, diabetes, hyperprolactinemia, thyroid dysfunction, etc.); 5: Recurrent miscarriage (2 or more consecutive spontaneous abortions with the same sexual partner); 6: Repeated implantation failure (those who have high-quality embryos but are not pregnant, >= 3 times); 7: estrogen >= 3000pg/ml on HCG day; 8: Exclusion criteria of fET: Moderate to severe OHSS risk; P >=1.5 ng/mL;Endometrial thickness<8 mm;

Design outcomes

Primary

MeasureTime frame
clinical pregnancy rate in fresh cycle;

Secondary

MeasureTime frame
Serum progesterone level on embryo transfer + 4-day;Serum estrogen level on oocyte retrieval + 4-day;implantation rate;miscarriage rate;ongoing pregnancy rate;Incidence of moderate to severe OHSS;

Countries

China

Contacts

Public ContactFenghua Liu

Guangdong Women and Children Hospital

liushine2006@163.com+86 139 2647 8318

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026